BxPC-3 is a human pancreatic adenocarcinoma cell line established in the mid-1980s from a biopsy of the body of the pancreas.1PubMed. Characterization of a new primary human pancreatic tumor line It occupies a distinctive niche among pancreatic cancer models because it is one of the few commonly used pancreatic ductal adenocarcinoma (PDAC) lines that carries wild-type KRAS, putting it in stark contrast to roughly 90 percent of human pancreatic cancers and most other PDAC cell lines. That single genetic feature makes BxPC-3 both unusually valuable for certain experiments and a source of confusion when researchers try to generalize from it.
Where the Cell Line Came From
BxPC-3 was derived from a primary tumor specimen, not from a metastatic deposit. The original patient had a histologically confirmed adenocarcinoma of the pancreatic body, and the line was characterized and reported in 1986.2PubMed. Characterization of a new primary human pancreatic tumor line Because it came directly from a primary lesion rather than from ascites or a liver metastasis, BxPC-3 is sometimes considered more representative of early or locally advanced disease than lines like AsPC-1, which was established from ascitic fluid. In practice, decades of continuous culture have blurred that distinction somewhat, but it remains a meaningful part of the line’s identity.
The Genetic Profile That Sets It Apart
The defining genetic feature of BxPC-3 is its wild-type KRAS status. KRAS mutations, most commonly at codon 12, are the near-universal initiating event in pancreatic ductal adenocarcinoma. Finding a PDAC cell line without one is unusual. BxPC-3 does carry other hallmark alterations of pancreatic cancer: a homozygous deletion of the CDKN2A/p16 locus, a homozygous deletion of SMAD4, and a TP53 missense mutation at codon 220 (a cysteine substitution).3Molecular Endocrinology. Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling The TP53 mutation is noteworthy because, unlike many p53 mutations in cancer, the codon-220 change is considered non-canonical and retains at least partial transcriptional activity.4Annals of Hepato-Biliary-Pancreatic Surgery. Mutations of p53 associated with pancreatic cancer and therapeutic implications That means BxPC-3 still has some functional p53 signaling, which distinguishes it from lines where p53 is fully inactivated.
The SMAD4 deletion removes a critical downstream mediator of TGF-β signaling. Loss of TGF-β’s growth-suppressive effects is a major step in pancreatic cancer progression, and BxPC-3 serves as a commonly used model for studying what happens when SMAD4 is absent. Research restoring TGF-β signaling in BxPC-3 cells has used inducible systems to re-express SMAD4 and observe the consequences, essentially turning a broken pathway back on to see what it normally does.5Molecular Endocrinology. Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling The combination of TP53 mutation with SMAD4 loss in a KRAS wild-type background has also been linked to a squamous phenotype in recent mouse modeling work, which is a more aggressive subtype of PDAC.6Cell Reports Medicine. Generation and characterization of KRAS wild-type pancreatic cancer mouse models with Trp53 and Smad4 or Tgfbr2 loss
Why Wild-Type KRAS Matters for Drug Studies
The vast majority of PDAC cell lines carry activating KRAS mutations, which drive continuous growth signaling through the RAS-RAF-MEK-ERK pathway. BxPC-3 lacks this oncogenic driver, yet it still shows elevated MEK activity.7Annals of Hepato-Biliary-Pancreatic Surgery. Mutations of p53 associated with pancreatic cancer and therapeutic implications The implication is that BxPC-3 activates that signaling pathway through alternative routes, possibly receptor tyrosine kinase overactivation or other upstream signals. This has practical consequences for drug sensitivity.
In comparative studies of MEK inhibitors across pancreatic cancer lines, BxPC-3 showed moderate sensitivity to agents like trametinib, while MiaPaCa-2 (which carries a KRAS G12C mutation) was highly sensitive and Panc-1 (KRAS G12D) was essentially unresponsive. The most striking finding was that combining the MEK inhibitor trametinib with the EGFR inhibitor afatinib produced a strong synergistic effect in BxPC-3, driving the effective dose down to very low, clinically relevant concentrations.8PLOS ONE. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers This fits the logic: if BxPC-3’s MEK activity is driven in part by EGFR signaling rather than by a mutant KRAS, then blocking EGFR at the same time should be especially effective. KRAS-mutant lines, by contrast, would keep firing the pathway downstream of where the EGFR block occurs.
The EGFR inhibitor erlotinib, which is FDA-approved in combination with gemcitabine for pancreatic cancer, also suppresses BxPC-3 growth as a single agent in a dose-dependent manner, triggering cell-cycle arrest and apoptosis.9PubMed Central. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line The takeaway for researchers is that BxPC-3 behaves like a PDAC that depends on receptor-level signaling rather than on a constitutively active KRAS, making it useful for modeling the minority of pancreatic cancers where targeted EGFR or MEK therapies might actually work well.
Gemcitabine Resistance
Gemcitabine remains a backbone chemotherapy for pancreatic cancer, and BxPC-3 has been used to model how resistance develops. Researchers have generated a gemcitabine-resistant derivative called BxPC-3/Gem by chronic exposure, and that resistant subline shows a resistance index of about 43-fold compared to the parental cells.10PubMed. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets The resistant cells also display visible morphological changes, consistent with the epithelial-to-mesenchymal transition commonly linked to drug resistance in PDAC. The same study found that emodin, a natural compound, could re-sensitize BxPC-3/Gem cells to gemcitabine by suppressing NF-κB signaling and its downstream targets.11PubMed. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets This kind of resistance modeling is common across PDAC lines, but BxPC-3’s wild-type KRAS background means the resistance mechanisms observed may differ from those in KRAS-mutant contexts.
Radiation Response
BxPC-3 is notably radioresistant. In head-to-head comparisons with Panc-1, BxPC-3 required roughly 1.6-fold higher radiation doses to achieve equivalent cell killing at doses of 3 Gy and above.12British Journal of Cancer. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation Interestingly, when researchers tried to create radiation-resistant variants by repeated fractionated exposure, BxPC-3 did not become meaningfully more resistant than it already was. The authors interpreted this as evidence that the parental line may already be close to its ceiling of radioresistance, or that it is more homogeneous in its radiation sensitivity than Panc-1. The cholesterol biosynthesis pathway emerged from unbiased screening as a druggable vulnerability for radiosensitization: the bisphosphonate zoledronic acid acted as a potent radiosensitizer in BxPC-3 and in the radiation-resistant Panc-1 derivative, with enhancement ratios in the range of 1.26 to 1.41.13British Journal of Cancer. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation
Metabolic Characteristics Under Hypoxia
Pancreatic tumors are famously hypoxic, and BxPC-3 has been a workhorse for studying the metabolic rewiring that occurs when oxygen is scarce. When BxPC-3 cells are placed under low-oxygen conditions, they upregulate the transcription factor HIF-1α, which in turn boosts expression of glycolytic enzymes like pyruvate dehydrogenase kinase 1 and lactate dehydrogenase A. The result is a shift toward anaerobic glycolysis even beyond what is typical for cancer cells. Silencing HIF-1α reverses this shift, reduces cell growth and invasion, and increases susceptibility to hypoxia-triggered apoptosis.14PubMed. The Effect of Silencing HIF-1α Gene in BxPC-3 Cell Line on Glycolysis-Related Gene Expression, Cell Growth, Invasion, and Apoptosis
A related line of research found that hypoxia in BxPC-3 cells also activates endoplasmic reticulum (ER) stress, which drives expression of the oxidoreductase ERO1L. This enzyme was in turn linked to enhanced aerobic glycolysis, suggesting a feedback loop where ER stress and metabolic reprogramming reinforce each other. Pharmacological inhibition of the PERK-EIF2α arm of the ER stress response largely blocked ERO1L induction, offering a potential point of intervention.15PubMed Central. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer
Angiogenic Signaling and Secretory Behavior
BxPC-3 cells actively secrete vascular endothelial growth factor (VEGF) and the matrix-degrading enzyme MMP-2, both of which promote new blood vessel formation and tissue invasion. Under hypoxia, secretion of both factors increases substantially. Treatment with benzyl isothiocyanate (BITC), a compound found in cruciferous vegetables, suppressed VEGF secretion by about 64 percent and MMP-2 secretion by about 79 percent in BxPC-3 cells at a 10 micromolar dose, even under hypoxic conditions.16PLoS ONE. Benzyl Isothiocyanate Suppresses Pancreatic Tumor Angiogenesis and Invasion by Inhibiting HIF-α/VEGF/Rho-GTPases: Pivotal Role of STAT-3 A separate study demonstrated that the membrane protein myoferlin plays a key role in how BxPC-3 cells export VEGF. Silencing myoferlin impaired VEGF exocytosis, suppressed cell proliferation, and reduced tumor volume in a chick chorioallantoic membrane assay.17PubMed. Myoferlin plays a key role in VEGFA secretion and impacts tumor-associated angiogenesis in human pancreas cancer Together, these studies show that BxPC-3 is a highly angiogenic cell line and a useful model for testing anti-angiogenic strategies.
Behavior in Animal Models
When implanted orthotopically into the pancreas of immunodeficient mice, BxPC-3 forms tumors that initially spread regionally to the spleen and retroperitoneum within about six weeks, though distant metastases are rare with the parental line.18PubMed. Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models This relatively limited metastatic reach makes BxPC-3 somewhat less aggressive in vivo than several other PDAC lines, at least in its unmodified form.
That changes dramatically with serial in vivo passaging. Researchers have taken BxPC-3 tumors, re-implanted them into new mice, and repeated the cycle six times. By the sixth passage, overall survival of host mice dropped from about 127 days to 52 days, and the average time to detectable metastasis shrank from roughly 14.5 weeks to 3.3 weeks. The passaged tumors showed widespread distant metastasis, not just faster primary growth.19PubMed Central. In Vivo Serial Selection of Human Pancreatic Cancer in Orthotopic Mouse Models Produces High Metastatic Variants Irrespective of Kras Status The same study performed parallel passaging with KRAS-mutant Panc-1 cells and saw a similar trajectory, suggesting that the process of becoming metastatic in vivo does not require KRAS mutation as a starting point. These serially passaged variants offer researchers a way to model aggressive, metastasis-prone disease using BxPC-3’s unique genetic background.
Immune Evasion and PD-L1 Expression
Pancreatic cancer is notoriously resistant to immunotherapy, and BxPC-3 has contributed to understanding one mechanism behind that resistance. When treated with insulin, BxPC-3 cells upregulate PD-L1 expression in a time- and dose-dependent fashion. This is relevant because the pancreatic tumor microenvironment often has elevated insulin signaling, and PD-L1 is the surface protein that tells attacking T cells to stand down. In co-culture experiments, insulin-pretreated BxPC-3 cells suppressed proliferation of activated human CD8-positive T cells, and that suppression was reversed by either the anti-PD-1 antibody pembrolizumab or by silencing PD-L1 with RNA interference.20PubMed Central. Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control The mechanism in BxPC-3 specifically involved modulation of the adaptor protein Gab1, differing from the routes used by other PDAC lines tested in the same study. This line-specific mechanistic diversity is a reminder that even within a single cancer type, immune evasion strategies vary.
Cancer Stem Cell Markers
BxPC-3 has been extensively profiled for cancer stem cell surface markers. Like other PDAC lines, it expresses CD44, CD326 (also known as EpCAM), and CXCR4 at varying levels. Flow cytometry in one study measured these at roughly 75 percent, 51 percent, and 63 percent of the cell population, respectively, along with about 47 percent aldehyde dehydrogenase-positive cells as measured by the ALDEFLUOR assay.21Scientific Reports. Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting Those are relatively high proportions, suggesting that the stem-like subpopulation in BxPC-3 cultures may be larger than in some other lines. However, broader comparative testing across five PDAC lines found that the side population, a functional marker of stem-like cells based on dye efflux, was consistently below 1 percent across all lines tested, including BxPC-3. Other markers showed substantial variability from line to line, underscoring how dependent stem cell identification is on which marker you choose.22PubMed Central. Comparative testing of various pancreatic cancer stem cells results in a novel class of pancreatic-cancer-initiating cells
Three-Dimensional Culture and Invasion Assays
Standard two-dimensional culture on plastic dishes captures only a fraction of how BxPC-3 behaves. The line has been widely used in three-dimensional models, including spheroid cultures and co-cultures with pancreatic stellate cells, the stromal cells responsible for the dense fibrotic tissue that defines pancreatic tumors. When BxPC-3 cells are co-cultured with stellate cells using modified hanging-drop methods, the resulting structures develop a desmoplastic reaction, tumor-like cell arrangements, and tissue architecture that more closely mimics the in vivo situation.23Theranostics. 3D approaches to model the tumor microenvironment of pancreatic cancer
Invasion assays using Boyden chambers and spheroid outgrowth show that BxPC-3 cells actively invade surrounding matrix, and this invasion can be attenuated by blocking monocarboxylate transporters MCT1 and MCT4, either pharmacologically or through gene knockdown.24Pancreas. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells These transporters shuttle lactate and other metabolic byproducts across the cell membrane, linking BxPC-3’s glycolytic metabolism directly to its invasive capacity. Blocking the transporters essentially disrupts the metabolic waste-removal system the cells depend on during energy-intensive activities like tissue invasion.
Quality Control and Genetic Drift
Any cell line that has been passaged for decades in hundreds of different laboratories will accumulate mutations, and BxPC-3 is no exception. A large-scale investigation of 278 tumor cell lines found that BxPC-3 was among nine lines showing variable short tandem repeat (STR) profiles after extended passage. Subclones of BxPC-3 shared only 80 to 94 percent STR identity with the original line, with apparent null alleles and mutations emerging over time.25PLoS ONE. Investigation of Cross-Contamination and Misidentification of 278 Widely Used Tumor Cell Lines This does not mean the line is unreliable, but it does mean that a BxPC-3 stock in one lab may not be genetically identical to a BxPC-3 stock in another.
Best practice is to authenticate by STR profiling whenever cells have been passaged for more than about six months, and several groups have adopted exactly this protocol, comparing results against published ATCC reference profiles.26PLOS ONE. Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells For anyone designing experiments with BxPC-3, especially studies where KRAS status is the entire rationale for choosing this line, confirming that the cells are still actually BxPC-3 is not pedantic housekeeping. It is essential to the experimental logic. Cross-contamination with a KRAS-mutant line would silently invalidate the whole premise of the work.
Where BxPC-3 Fits Among Pancreatic Cancer Models
Researchers working in pancreatic cancer typically have a handful of cell lines to choose from, and each carries its own biases. MiaPaCa-2 and Panc-1 are KRAS-mutant lines with differing drug-sensitivity profiles; AsPC-1 was derived from metastatic ascites and carries its own set of alterations. BxPC-3 fills a specific gap as a KRAS wild-type model with a squamous-like phenotype, loss of TGF-β signaling through SMAD4 deletion, and an intact (if altered) p53 pathway. Its moderate sensitivity to MEK inhibition, robust angiogenic secretion, intrinsic radioresistance, and well-characterized behavior in orthotopic mouse models make it a go-to line for questions where KRAS-independent signaling is the variable of interest.
The catch is representativeness. Only about 5 to 10 percent of human pancreatic ductal adenocarcinomas are KRAS wild-type, so BxPC-3 models the exception rather than the rule. Findings in BxPC-3 should not be automatically extrapolated to the typical PDAC patient, whose tumor almost certainly carries a KRAS mutation. The most informative studies use BxPC-3 alongside KRAS-mutant lines and look for differences that track with genotype, rather than treating any single line as representative of the disease.